BioMarin Pharma (NASDAQ: BMRN) announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingOctober 15, 2015 7:54 AM Sarepta Therapeutics' (SRPT) Eteplirsen May Be Reviewed on Jan. 22 by FDA Panel - BloombergOctober 14, 2015 11:43 AM